Menarini

Focused on people

Menarini

Focused on people

GRUPO
MENARINI
www.menarini.es

"People, finding a solution for every disease and providing more health and better quality of life are our reason for being"

Table of Contents

01 About us

1.1 Menarini Group International / 6
1.2 Menarini Spain / 7
1.3 Menarini Latin America / 9

02 Committed to health

2.1 Therapeutic areas / 10
2.2 Self-care of health / 12
2.3 Licenses / 12
2.4 Research, development and innovation / 12
2.5 Quality / 15
2.6 Commitment to healthcare professionals / 16

03 Focused on people

3.1 Ethics, deontology and transparency / 18
3.2 Human capital / 20
3.3 Menarini responsible / 22

04 Menarini Connected

4.1 Digital health / 26
4.2 Mobile applications / 27
4.3 Against digital isolation / 28

01 About us

1.1. MENARINI GROUP INTERNATIONAL

The Menarini Group, with its headquarters in Florence, is the leading Italian pharmaceutical company in the world. It has more than 125 years of history and is present in more than 130 countries around the world.

Menarini's more than 17,000 people work every day to provide innovative health solutions and improve people's lives.

We have seven research centres and 16 production plants that manufacture more than 580 million units of medicines annually.

The company's growth has been constant, both in terms of turnover and staff, and is the result of a strategy based on research, innovation and internationalisation. Currently, the company focuses its activity on the areas of cardiovascular risk, respiratory, pain management, digestive system and men's sexual health. We are also working on research and development of products in other therapeutic areas such as oncology.

Countries where Menarini is present

TURNOVER OF MENARINI GROUP INTERNATIONAL

EMPLOYEES OF MENARINI GROUP INTERNATIONAL

1.2. MENARINI SPAIN

Menarini Spain is one of the group's strategic subsidiaries and is one of the top 13 companies in the Spanish pharmaceutical sector.

Its headquarters are located in Badalona, and it is the largest private company in this city in terms of turnover - a total of 254 million euros in 2019 (+3.6% vs. 2018) - as well as in the number of workers - a total of 760 people.

With a built area of 13,000 m², the facilities house the offices, a production plant and one of the Group's seven R&D&I centres. The company produces 58 million units of medicines per year, 73% of which are exported.

"The Menarini Group is present in 136 countries around the world"

The products marketed are mainly intended for the following therapeutic areas: respiratory, cardiovascular risk, gastroenterological, pain management, anti-anaemic, anti-gout, anti-inflammatory.

"We are one of the top 13 companies in the European and Spanish pharmaceutical sector"

Menarini Spain is made up of the companies Laboratorios Menarini, S.A.; A. Menarini Latin America, S.L.U.; Menarini Consumer Healthcare, S.A.U.; Guidotti Farma, S.L.U.; Retrain, S.A.U. and Laboratorios Fermon, S.L.U.

In the ranking of 300 pharmaceutical companies of the *Monitor Empresarial de Reputación Corporativa (MERCO)*, Menarini occupied the 12th place in 2019, rising four places since 2015.

A BIT OF HISTORY

Menarini is a pharmaceutical company founded in Naples in 1886 which began its activity in Spain in 1961 after merging with the Spanish laboratory Puig Sala and acquiring the name Laboratorios Menarini S.A. In 1972 the company moved its headquarters from Barcelona to Badalona and underwent several extensions until it reached its current 13,000 m².

MISSION

People, finding a solution for every disease and providing more health and better quality of life are our reason for being.

VISION

We want to be a leading company committed to people's lives, which promotes innovative initiatives that generate knowledge and provide more health.

VALUES

Focused on people, our best asset.
Together we have built our identity and together we build our future.

Innovation, creativity, dynamism and versatility help us to face new challenges and generate opportunities.

Excellence, we work every day to achieve the highest level of quality by rigorously complying with procedures and opting for training in a process of continuous improvement.

Responsibility, we are responsible to society, to our employees and to our environment.

1.3. MENARINI LATIN AMERICA

In 1979 Menarini decided to expand its activity to Latin America. Since then, Menarini Spain has been responsible for internationalization plans in the area.

Menarini began its presence in the area by locating its headquarters and production plant in Guatemala, with distribution companies in El Salvador, Honduras, Nicaragua, Costa Rica, Panama, the Dominican Republic and Belize. In total, more than 700 people work in Menarini Centroamérica y el Caribe.

The company has an outstanding presence in the Central American market, where its main activity corresponds to the areas of cardiovascular risk, inflammation and pain.

In 2019, Menarini Centroamérica y el Caribe experienced growth of 25% with a turnover of more than 118.6 million euros. It has a structure of 770 people and occupies the 1st place among the companies of the pharmaceutical sector in the area.

With a presence in Mexico since 2009, we have our own structure of 210 people. In 2019 the turnover was 25 million euros. Since March 2017 the Menarini Group has consolidated its presence in Latin America. AMLA Peru had a turnover of 5.4 million euros in 2019 with a structure of 24 people. AMLA Colombia has a turnover of 2 million euros and a structure of 35 people. In addition, thanks to commercial distribution agreements and marketing licences with local pharmaceutical companies, Menarini products are distributed in Argentina, Brazil, Chile and Ecuador.

02 Committed to health

2.1. THERAPEUTIC AREAS

Menarini, as a company that researches, develops and produces medicines, focuses its activity mainly on the areas of pain management, cardiovascular risk, the digestive and respiratory systems and men's sexual health.

CARDIOVASCULAR RISK

Our commitment to cardiovascular health has been consistent. Currently, cardiovascular diseases are the leading cause of death in our country. Therefore, helping to prevent these pathologies and improve the quality of life of patients is key for us.

High blood pressure. It is one of the most important cardiovascular risk factors, along with obesity, dyslipidemia and diabetes. In Spain, more than 14 million people suffer from hypertension.

Many of these pathologies are undiagnosed, since in most cases hypertension does not present evident symptoms.

Although genetic factors influence high blood pressure, lifestyle also plays an important role in its management. Proper weight control and diet, as well as physical exercise, are essential for maintaining proper blood pressure.

Angina pectoris. It is a common form of presentation of coronary disease and is a major health problem due to its high prevalence.

Stable angina pectoris is a clinical, sometimes disabling syndrome characterized by pain in the chest, jaw, shoulders, back or arms that occurs with exercise or emotional stress and improves with rest or medication. Lifestyle changes, control of risk factors for coronary disease and patient education are, along with treatment, basic pillars for the management of this pathology.

Gout. It is a rheumatic disease caused by the accumulation of uric acid crystals in joints and other tissues. Uric acid crystal deposits cause severe pain and swelling of the joints, usually in the big toe, knee or ankle. So-called "gout attacks" can last for hours or even days.

Gout is up to four times more common in men than in women, and middle-aged men are more likely to suffer from it.

There is a growing body of scientific evidence showing that people with gout are at increased risk of cardiovascular and kidney disease. So it's more than just joint inflammation.

Diabetes. Type 2 diabetes mellitus is a metabolic disease characterized by abnormally high blood sugar (hyperglycaemia). Overweight and obesity are the two most important risk factors for this disease. Type 2 diabetes accounts for about 80% of diabetes cases in our country.

In addition to drug treatment, this condition requires an appropriate diet and exercise plan to control blood sugar levels.

PAIN MANAGEMENT

The area of pain management is one of the main pillars of research for Menarini. At our R&D&I centre in Badalona we have researched and developed dexketoprofen trometamol, Enantyum®, registered throughout the European Union and which has become one of the reference medicines in this area, as well as the combination of dexketropofen and tramadol, Enanplus®, indicated for the relief of moderate to severe acute pain.

DIGESTIVE SYSTEM

Irritable bowel syndrome (IBS) is the most common, highly prevalent, and frequently reported gastrointestinal functional disorder. IBS has a benign course and is characterized by the presence of recurrent gastrointestinal symptoms, such as abdominal pain and distension along with alterations in depositional habit. When this disorder becomes chronic, the impact on the quality of life of affected patients is considerable.

RESPIRATORY

Research in the respiratory area is key to improving the quality of life of patients with Chronic Obstructive Pulmonary Disease (COPD), asthma and other lung conditions.

COPD. A common disease that can be prevented and treated. It is characterized by a persistent limitation of airflow, which is usually progressive and is associated with a chronic inflammatory response in the lungs to harmful particles or gases. Smoking is the main risk factor for this disease. COPD causes more than 18,000 deaths annually in Spain, and studies show that it is the leading cause of preventable death in our country. COPD is expected to be the fourth leading cause of death worldwide by 2030.

Allergy. Allergy is an exaggerated response of the immune system to certain substances called allergens. The most common allergens are pollens, environmental fungi, dust mites and the epithelia of some animals. Contact with these allergens triggers the release of histamine, which causes an exaggerated reaction of the cells in our body. It is estimated that 20% of the population suffers some kind of allergic reaction and this figure seems to be increasing.

Asthma. Chronic inflammatory airway disease that obstructs (reversibly) the airway and causes bronchial hyperreactivity. Asthma is caused by an uncontrolled immune system response, which leads to inflammation of the bronchi. Cases may be persistent or intermittent and may occur at any age. In Spain it has a prevalence of 3 million people and asthma attacks cause 2% of hospital admissions. The rate of under-diagnosed patients reaches 50% while poor symptom control is observed in about 60% to 70% of the cases.

MEN'S SEXUAL HEALTH

At Menarini we break taboos in men's sexual health and help patients find effective therapeutic solutions.

Erectile dysfunction. It is defined as a persistent difficulty in presenting and maintaining an erection sufficient for normal sexual activity. It affects both the patient's and his partner's well-being, and may be due to physical and/or psychological causes. This pathology occurs more frequently in men over 40 years of age and its incidence increases with age. Other factors such as smoking, overweight, diabetes and depression can also play a role.

Premature ejaculation. It presents data of variable prevalence according to its clinical definition, which can range from 1-3% to 20-30% if more subjective aspects of control and discomfort are taken into account. Its prevalence also increases with age; however, it is one of the most under-diagnosed alterations in male sexual health.

The complete Menarini vademecum can be consulted on the company's website.

2.2. SELF-CARE OF HEALTH

At Menarini we are also committed to self-care for health and for this reason we market over-the-counter products available in pharmacies (medical devices, food supplements, dietetic foods and cosmetics).

Thus, we have an important catalogue of products in different areas, ranging from pain management (**Novidol®**), oral health (**Oddent®**), to digestive system (**Kaleidon®**), women's health (**Ginegea®**), hair care (**Capicaps®**), children's health (**Hidropolivital®**), the functioning of the urinary tract (**Proxamol®**) or food supplements (**Sustenium Plus®**).

2.3. LICENSING

Menarini has built up an important international reputation as an in-licensing company. Worldwide, the Group has signed more than 150 license agreements with various pharmaceutical companies.

Our goal as licensees is to ensure that these medicines are treated uniquely at all levels of the organization. We carry out research and development on most of the drugs we have in-licensed to improve our knowledge and many of them are manufactured at our production sites.

2.4. RESEARCH, DEVELOPMENT AND INNOVATION

The commitment to research has been present in Menarini since its origins. For Menarini, R&D is a fundamental pillar of our activity and for this reason we dedicate a significant volume of material and human resources to it. We invest 10% of the annual budget and have a team of more than 900 people dedicated to the research and development of new health solutions in our seven R&D centres around the world (Pisa, Florence and Pomezia in Italy; Badalona in Spain; Berlin in Germany; San Diego in the United States; and Singapore).

We rely on research to develop new drugs that add value to currently available treatments, or that may be the cure for diseases that do not yet have effective solutions.

RESEARCH IN MENARINI SPAIN

Menarini Spain has one of the group's most relevant R&D centres. In fact, it is the reference centre for pharmacovigilance of all the Menarini Group's research studies worldwide. With a team of 60 highly qualified professionals, it works in:

- New pharmaceutical forms and preclinical development of new molecules.
- Development and technological innovation projects to optimize production processes and the quality of medicines.
- National and international clinical studies for new medicinal products and post-marketing studies.

Menarini Spain's R&D&I team works in close collaboration with the other research centres of the Group and also with specialised external institutions, clinical research units located in hospitals, primary care centres, universities and other research entities.

In addition, the R&D centre in Badalona is integrated in the National Biomedicine Programme (PROFARMA Action). It is included in the Research Promotion Program of the Ministry of Science and Technology (PROFIT) and is part of the Plan for the Promotion of the Pharmaceutical Industry. Under this plan, we carry out scientific and technical training exchanges with the Ministries of Health, Industry and Innovation, and with other public entities such as the Centre for Technological and Industrial Development (CDTI). We also collaborate on a permanent basis with various scientific and academic entities, both for pharmaceutical development activities and for conducting clinical trials.

"We are the reference centre for pharmacovigilance of all the Menarini Group's research studies worldwide"

DEXKETOPROFEN TROMETAMOL: RESEARCHED AND MANUFACTURED IN SPAIN

In the 1990s, Menarini's R&D centre and production plant in Badalona led the development of the dexketoprofen trometamol (DKP) molecule from the first stages of research to its marketing.

Since then, practically the entire manufacturing process of Enantyum® is carried out in this plant. Specifically, in 2018 it has produced more than 44 million units, representing 63% of total production. This analgesic is currently marketed in 24 countries.

With this drug, Menarini became the first company to work with the Spanish Agency for Medicines and Medical Devices (AEMPS) to obtain a European registration in all member states. This development has been a turning point for the Menarini brand in Spain.

R&D&I AS A CORNERSTONE

In recent years Menarini's research programmes have focused on the study of cardiovascular diseases, intestinal motility disorders, pain / inflammation and, in particular, oncology.

In addition, Menarini is investing in medical research projects. Good proof of this is the work in 15 clinical trials, mainly in the field of oncology.

Precisely in 2018, the research and development company for new cancer therapies Selvita has transferred to Menarini Ricerche, a Menarini Group company, phase I/II of the clinical development of MEN1703/SEL24, currently ongoing in the USA for the treatment of refractory relapsed (R/R) acute myeloid leukaemia (AML).
Selvita and the Menarini Group reached a worldwide license agreement for the MEN1703/SEL24 in March 2017. After a period of mutual collaboration, Menarini Ricerche has taken responsibility for all clinical development activities.

In 2016 an agreement was signed with Chugai for the development of MEN1611 and in 2012 another with Oxford Biotherapeutics to bring 5 monoclonal ACs up to the clinical phase, of which 2 are already in clinical development (MEN1112 and MEN1309).

All of them are oncology projects that reflect Menarini's investment in R&D.

VERY REVEALING DATA

In its more than 55 years in Spain, Menarini has never recorded safety problems that have led to the loss of marketing authorisation for one of its medicines.

In 2018, Menarini Spain provided a total of 9,769 hours of job training. The manufacturing staff has received more than 80 h/year of training in quality, occupational risk prevention and the environment.

The selection of an active ingredient and/or excipients may take more than one year in order to find the most suitable and highest quality ones.

2.5. QUALITY

For Menarini, the quality of the medicines comes first and therefore we apply demanding quality standards that begin with the selection of raw material suppliers, to continue with the control of the manufacturing environment.

Also, once our medicines have arrived at the pharmacy, we work to ensure good quality treatment. Therefore, we provide scientific information to physicians, pharmacists and other healthcare professionals to ensure that their knowledge of the product is complete and comprehensive.

Control also means listening. In this regard, Menarini maintains constant contact with healthcare professionals to obtain feedback on our medicines and products, so we monitor all possible adverse reactions reported anywhere in the world.

This commitment to quality is embodied in obtaining certifications in accordance with compliance with:

- Good Manufacturing Practice (GMP)
- Good Clinical Practice (GCP)
- Good Pharmacovigilance Practice (GPvP)

The effort made by our company to implement a suitable quality policy was recognised in 2000 with the achievement of the ISO 9001 compliance certificate.

CERTIFIED ISO 9001

"In its 55+ years in Spain, Menarini has not registered any serious safety alerts with any of its medicinal products"

2.6. COMMITMENT TO HEALTHCARE PROFESSIONALS

MENARINI SCIENTIFIC AREA

Menarini maintains a strong commitment to the continuous training of healthcare professionals. As a result, in 1990, the Menarini Scientific Area *(Área Científica Menarini)* was born, whose main objective is to provide quality training in the field of health.

In its almost 30 years of work, more than 21,000 training activities have been carried out, in which more than 32,500 professionals have participated as speakers and another 545,000 have broadened their knowledge.

Scientific societies, professional associations, medical sciences academies, educational institutions, health centres, hospitals and health administrations collaborate and participate regularly in these activities, which range from round tables to practical workshops, national and international congresses or courses, seminars and conferences.

With the aim of offering innovative activities that are more specific and adapted to specific profiles and needs, Menarini collaborates with different Spanish academic bodies and medical-scientific societies in different chairs and master's degrees.

UCAM-SEPAR-MENARINI Chair of Pneumology launched in 2018 a new Master's Degree in Smoking Control and Cessation.

UB-SEMI-MENARINI Chair of Internal Medicine promotes teaching and research activities in the field of internal medicine. In 2018, the Master's Degree in Emergency Medical Care was completed.

Master's Degree in Clinical Management of Care Units promoted by the Spanish Society of Endocrinology and Nutrition (SEEN), the Menéndez Pelayo International University (UIMP) and Menarini.

Master's Degree ASECMA / SCCMA of Major Ambulatory Surgery

Master's Degree in Care and Education of People with Type 2 Diabetes promoted by the redGPDS Foundation, in collaboration with the Francisco de Vitoria University.

Master's Degree in Diagnostic Imaging in Cardiology

Distance-learning Postgraduate Master's Degree in Advances in the Diagnosis and Treatment of Sleep Disorders

Distance-learning Postgraduate Master's Degree in COPD

Master's Degree in Diabetes in Daily Clinical Practice

GENERATING MEDICAL AND SCIENTIFIC COMMUNITY

Menarini Spain organizes a large number of meetings aimed at the health and scientific community with the aim of discussing the latest trends in the sector.

Thus, every year it organizes the Barcelona Boston Lung Conference, a meeting led by professors Alvar Agustí, director of the Institute of the Thorax of the Hospital Clinic of Barcelona, and Bartolomé Celli, of the Harvard University. This conference brings together in each edition around 300 senior and young pulmonologists to delve into the latest knowledge of respiratory diseases from the hands of leading international figures in the field.

The Menarini Scientific Area has also supported, for years, the Toxicology Refresher Courses, the Continued Education Course in Major Outpatient Surgery, the COPD Refresher Course through 4 case reports, the Thoracic Ultrasound Course in Pneumology Services, the Medical Refresher Course by the Emergency Department of regional hospitals, the Ultrasound and Renal Doppler Course and the Cardiology Observership, among others.

"Menarini Scientific Area is recognised as a pioneer, reference and leader in continued education"

03 Focused on people

At Menarini we are socially responsible with the aim of reconciling the processes and interests of our business activity with the values and demands of society. Our commitment is unavoidable in the field of health and our closest environment.

3.1. ETHICS, DEONTOLOGY AND TRANSPARENCY

Menarini Spain has been characterised by a long pharmaceutical tradition based on a commitment to excellence, innovation, responsibility, solidarity and respect for applicable laws and regulations.

Currently, society has been demanding greater transparency, ethics and commitment from companies to effective anti-corruption policies, respect for free competition and financial transparency.

Menarini Group Spain, like Menarini Group International, has acquired an active role in participating in the self-regulation bodies of the pharmaceutical sector and the innovative medicine industry.

Our interest is, together with compliance with the laws and regulations in force in the sector, to promote and integrate ethical behaviour and values in line with good practice in the pharmaceutical industry. That is why, since May 2013, our employees and collaborators have committed themselves to respecting the values set out in our Code of Conduct.

Our ethical commitment extends to the patients who benefit from our medicines and products, contributing to the prevention, diagnosis and treatment of their diseases and to the improvement of their quality of life.

Our Code of Conduct states that all activities performed by employees, managers and/or collaborators must be carried out with the utmost honesty, integrity and good faith, ensuring legal and regulatory compliance and fair competition. We are also committed to respecting at all times the legitimate interests of customers, employees, partners and the communities in which we are present.

Menarini Spain is a member of the National Business Association of the Spanish Pharmaceutical Industry (Farmaindustria), which groups together most of the pharmaceutical laboratories established in Spain, and of the Association for Self-Care of Health (ANEFP), which groups together and represents the companies that manufacture and/or distribute in Spain both medicines authorised without a prescription and not reimbursed by public funds, as well as other products aimed at self-care of health.

We are committed to ensuring that our activities are carried out in accordance with the strictest ethical principles of professionalism and responsibility, as set out in the Codes of both associations and in compliance with all current regulations, for the benefit of the Health Administration, the pharmaceutical industry itself and the protection and improvement of public health.

As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of Farmaindustria, Menarini Spain has registered, since 1 January 2015, all the value transfers it makes to healthcare professionals and organisations, related to R&D, donations, training, scientific-professional meetings and the provision of services for subsequent publication.

"Tradition based on excellence, responsibility, innovation, solidarity and respect"

3.2. HUMAN CAPITAL

Starting with its own staff, Menarini advocates for equal opportunities between men and women, which is reflected in an equal distribution of staff by gender.

We have demonstrated our commitment to promoting and maintaining employment. There has never been a reduction in staff and recruitment has been constant. We promote job stability - 90.9% of contracts are permanent -, work-life balance, and the professional development of our employees.

Menarini Spain draws up an annual training plan adapted to the needs of each area. There is common training for the entire staff on quality, occupational risk prevention and the environment, as well as training on compliance and other disciplines, which in 2018 amounted to a total of 9,769 hours of occupational training.

On the other hand, the Company facilitates the access of young people to the working world with internship programs in the company for university or master's degree students, as well as professional training.

"90.9% of the contracts are permanent"

Menarini has been contributing financially to the educational costs of its employees' children for over 20 years with the aim of enabling them to achieve the highest possible level of education.

In addition, Menarini has a Mailbox for ideas. A project that promotes the active participation of all employees in the process of continuous improvement and development of the company, thanks to ideas and suggestions that are converted into concrete actions.

Buzón de Ideas
Tu idea puede cambiar nuestro mundo

STAFF BY AREAS OF THE COMPANY. 2018

HOURS OF STAFF TRAINING. 2018

HEALTH AND SAFETY

Laboratorios Menarini has an Occupational Health and Safety Management System which allows to minimize and control the occupational risks of our staff.

Since 2005, the Company has held the OHSAS 18001 occupational health and safety certification, successfully passing successive audits and being one of the first companies in the sector to achieve this accreditation. Specifically, this rule applies to the development, manufacture and marketing of medicines.

The number of hours of absenteeism among Menarini Spain personnel during the 2019 financial year was 45,668.

"We have obtained and maintained the OHSAS 18001 certification"

CERTIFIED LR OHSAS 18001

3.3. MENARINI RESPONSIBLE

SOCIAL ACTION IN OUR TERRITORY

Badalona is our home and that of many of our employees, which means that we have important links with the city and its inhabitants.

We assume social commitments to bring together the interests and processes of our business activity with the values and demands of society.

Committed to health and to our closest environment, Menarini Spain wants to give back to the community part of what it receives from it.

As a result of our experience, we have structured our corporate social responsibility into a five-point methodology:

1. Develop a conscious and constant solidarity.
At Menarini we have found that continuity projects give better results than one-off ones, which is why we tend to sign long-term collaboration agreements. Our experience tells us that the involvement of the parties has a direct impact on the success of the initiative, so we make sure it is important by following a three-pronged strategy: visiting and getting to know the projects first hand, maintaining constant contact with the entities, and including in the agreement the responsibilities of the two parties involved.

2. Attend to the symptoms and above all, act on the causes.
We try to understand the reasons and at the same time we directly influence the causes, through training projects, integration projects, purchase of services or even occasional donations to solve urgent needs.

3. Helping those who help. At Menarini we have observed that we must approach the entities and join the projects they already carry out. They are the ones who know the territory and its needs best. This will lead to positive, comprehensive and lasting results.

4. Focus on projects in our field.
Our sector is the pharmaceutical one and we are experts in research, science, health, etc. Therefore, we try to collaborate with projects in the world of health, which is the one we know best and where we can contribute most.

5. Identify the needs of our environment.
We detect the needs where we are, and we commit ourselves to the fourth world. However, our approach is global and, in emergency situations, we are in solidarity with the third world.

In 2017 Menarini Spain joined the United Nations Global Compact, committing itself to implement its 10 principles and to report annually on its progress through its sustainability report.

HELPING

FUNDACIÓ ATENEU SANT ROC

Ateneu Sant Roc Foundation: Social action entity that promotes socio-educational projects in the Sant Roc neighbourhood, aimed at children, young people and adults, with a special emphasis on the most vulnerable groups at risk of social exclusion.

We collaborate with the Laila Project (which facilitates the integration of women from different cultures and backgrounds) and the Elna Family Space Project (aimed at young women with limited resources to strengthen the emotional relationship with their babies).

Càritas

Formació i Treball
La Fundació amiga

Càritas Diocesana de Barcelona-Formació i Treball: It welcomes and works with people in poverty and need so that they reach personal independence and freedom.

We collaborate with the socio-occupational centre, *Taller Sant Isidre*; with the D'INS hotel management school, which offers a second chance to young people at risk of social exclusion and with the *Roba Amiga* project for recycling used clothes.

Fundació Joventut Badalona

Fundació Club Joventut Badalona: We collaborate with the wheelchair basketball team with the aim of promoting and organizing different activities to raise social awareness and educate in values.

Generalitat de Catalunya
Departament d'Acció Social i Ciutadania
Direcció General d'Atenció a la Infància i l'Adolescència
C.R.A.E. Mª Assumpta

Maria Assumpta Residential Educational Centre: A centre dependent on the Department of Social Welfare and Family of the Generalitat de Catalunya which takes in children in situations of distress.

For more than 20 years we have helped the centre by organising a drawing competition and a Christmas party for the children and teenagers in their care.

Ajuntament de Badalona

Badalona City Council: We have promoted the project "Badalona cardioprotected city" with the installation of defibrillators in 26 pharmacies in the city.

We also promote science among the youth, through collaboration in the Scientific Days of Secondary Education in Badalona.

Red TBS

Network against tuberculosis and for solidarity: We collaborate with the TBS Network in public activities of sensitization, awareness, information and training related to tuberculosis.

THOSE WHO HELP

Educo: A Spanish NGO for the defence and protection of children through sponsorship and school meal aids. Menarini participates in the *'Becas Comedor'* project, whose objective is to guarantee a complete and healthy meal a day to children at risk of social exclusion in the different Spanish autonomous communities.

International Cooperation: This NGO works to inculcate a culture of solidarity among young people, promoting volunteerism and social participation. Menarini collaborates with the 'A Smile for Christmas' campaign, where workers buy gifts for children at risk of social exclusion.

"We help entities that work for the well-being of people"

AWARDS

Menarini recognised as a "Positive Company 2019" for its commitment to the environment

Menarini has been awarded the "Positive Company 2019" prize, a distinction which recognizes good business neighbourliness as a social commitment to proximity and which has been granted to it for being a company highly committed to its closest environment. Menarini carries out different solidarity activities and is deeply involved in the well-being of the people of Badalona.

OTHER SOCIAL ACTIONS

At Menarini, since 2007 we have been carrying out regular medicine donations to the NGO Pharmacists without Borders Spain (FSFE) drug bank, which selects other recipients through strict controls. Our medicines have reached more than 50 countries around the world affected by conflict, natural disasters and areas of great need. We also make special donations in the event of major natural disasters.

Menarini also collaborates with *Banco Farmacéutico*, the pharmacy's NGO, to facilitate access to medicines for elderly people living alone in the municipality of Badalona.

Menarini's workers, together with the Company, have carried out campaigns to collect basic food products in collaboration with the *Fundación Banco de Alimentos*. In 2019, all records were broken, reaching 2,000 kg of donated food, which is more than the amount collected in the previous two years.

From our headquarters in Badalona and our delegations, we have joined the project "Caps for a new life" promoted by the SEUR Foundation which, by collecting plastic caps, helps children with illnesses that require costly treatments they cannot afford.

ENVIRONMENT POLICY

For Menarini it is essential to make growth compatible with the minimum impact on the environment.

In fact, in 2001 Laboratorios Menarini became one of the first pharmaceutical companies to receive ISO 14001 certification for the environmental management of its drug design and manufacturing activities.

In addition, in 2004 it obtained certification of participation in the European environmental management and audit system EMAS, becoming the first company in the pharmaceutical products manufacturing sector to obtain this certification in Catalonia and the second in Spain.

One of our strategic objectives is to improve the management of environmental resources. Thus, although the capacity of the Badalona production plant has increased, Menarini has reduced the energy used by each unit manufactured.

Every year, Laboratorios Menarini publishes its Environmental Statement, which is verified by an independent entity and published on our corporate website.

In 2019 Menarini established a "plan of attack" to eliminate plastic from the Badalona headquarters. The 50cl bottles in the vending machines have been removed and the ones in the meeting and canteen caterings have been replaced by 1L returnable glass bottles. In addition, plastic cups have been replaced by paper cups. With these measures we are eliminating a ton of plastic from the environment.

CERTIFIED ISO 14001

EMAS GESTIÓ AMBIENTAL VERIFICADA ES-CAT-000156

"One of our strategic objectives is to improve the management of environmental resources"

COVID-19 PANDEMIC

Menarini has collaborated in funding research projects on SARS-CoV-2 and COVID-19 in the wake of the pandemic.

The Carlos III Health Institute, a body that depends on the Ministry of Science and Innovation, has received a donation of 70,000 euros to help finance the research projects it is working on.

On the other hand, the #YoMeCorono initiative, in which the Germans Trias i Pujol Hospital, the Fight against AIDS and Infectious Diseases Foundation and the Irsicaixa AIDS Research Institute are participating, has received another 70,000 euros. This initiative is working on two lines of research: a clinical trial to demonstrate the efficacy of a strategy to stop the transmission of the SARS-CoV-2 virus and a study focused on the development of antibodies, drugs and, ultimately, a vaccine against the coronavirus.

04 Menarini connected

4.1. DIGITAL HEALTH

Menarini has a historical commitment to promoting digital health and mobile health (mHealth) in order to respond to the needs of healthcare professionals and patients.

In 1996 it became the first pharmaceutical company with its own domain in Spain (menarini.es) and, in 2002, the first website of the pharmaceutical industry in Spain with a seal of approval for the quality and rigor of its health content (Accredited Medical Website of the Official Physician Association of Barcelona). In 2010, the Company already had 12 websites and a YouTube channel, and began experimenting with new digital tools applied to training.

In 2013, Menarini began intense work in the field of mobile health applications, becoming the first laboratory in Spain to achieve the 'AppSaludable' distinction awarded by the Regional Government of Andalusia, with the Salud 2.0 application among professionals.

"We were the first pharmaceutical company with its own domain in Spain: **menarini.es**"

4.2. MOBILE APPLICATIONS

Menarini, with a strong commitment to digital health and a desire to promote greater use of mobile health (mHealth), has developed several apps aimed at patients and healthcare professionals.

FOR HEALTHCARE PROFESSIONALS

MEDICAL MEETING CALENDAR
New Menarini app which allows access to information on congresses and events related to medical specialities within a year and with continuously updated content. With this app one can check the dates and place of the congresses, access the websites of the different events, get information about the weather forecast before travelling and have a currency converter and a translator.

APPTECA
It is a library of 6 mobile apps on topics related to cardiovascular disease. Its objective is to help in the resolution of many of the doubts that arise in clinical practice and to cover the needs of healthcare professionals in the assistance to their patients, applying gamification techniques to improve the training. This app is promoted by the Spanish Society of Cardiology (SEC) and the Spanish Society of General and Family Medicine (SEMG), in collaboration with Menarini.

CONTROL ASMAPP (WEBAPP)
It is a project born from the interest of SEMERGEN and SEPAR in the best control of asthmatic patients. The app's wide range of functions represents a very useful tool for the increased monitoring of patients and the recording of their data in a secure and accessible environment.

TRIVIFARMA
This app allows pharmacists and other healthcare professionals to train in Health 2.0 through a fun game. It's about answering a series of questions about digital tools. Trivifarma combines the recreational aspect with the rigor of the contents, applying gamification techniques to improve the training.

UNIVERSAL PHARMACIST SPEAKER
Multilingual application that facilitates communication between patients and pharmacists. It has hundreds of questions, phrases and answers with audio, translated into 12 languages: English, French, German, Arabic, Moroccan Arabic, Chinese, Italian, Polish, Portuguese, Romanian, Russian and Dutch. In this way the patient can explain to the pharmacist the reason for the visit and the symptoms, so that the pharmacist can carry out the most frequent dispensing and advice according to the disorder in question.

FOR PATIENTS

DISFRUTA +
Aimed at patients and the general public, it helps to improve sexual health in a simple and fun way. The most relevant topics are explained in clear language, and questions are asked to check their correct understanding. In addition, it includes a functionality that helps the user to prepare his consultation with a professional.

TRIVIGOTA: TO BETTER UNDERSTAND GOUT
It is aimed at people with gout to better understand their disease through questions and answers. This app helps to promote a healthy lifestyle, provides more information on physiological aspects of the disease and even historical issues or beliefs and myths related to gout, all in a fun and friendly environment.

MENAINHAL
It allows the healthcare professional to show the patient the correct way to use the Genuair and Easyhaler inhalers through augmented reality. The app can also be downloaded by the patient, who can review these instructions in 3D whenever desired. In both cases the aim of the App is to help adherence to treatment and ensure correct use of asthma and COPD treatments.

4.3. AGAINST DIGITAL ISOLATION

After several years in the digital environment, at Menarini we believe that the success of eHealth initiatives depends on increasing the number of people involved. In 2010, we launched the project #Salu20 to bring professionals closer to experiences in Health 2.0. With this in mind, we carried out 12 training sessions in 6 autonomous communities, which were attended by more than 800 people.

As a result of those days, the tag #Salu20, which brought together the conversation generated on Twitter before, during and after our sessions on Health 2.0, became a reference hashtag and one of the most used health tags.

In 2014, four years later, we realized that healthcare professionals, institutions, companies and patients who had jumped on the bandwagon of new technologies were far less than expected. There was still a digital divide in the sector. As a result of this reflection, we have launched the Sherpas 20 project, together against digital isolation. This initiative aims to provide individuals and organizations with a model for implementing digital health initiatives to respond to their concerns and needs.

With this comprehensive approach, at Menarini we want to be the driving force behind making eHealth a reality in Spain.

#SHERPAS20

An initiative known as the #sherpas20 movement, which aims to bridge the gap in society and the health sector in the use and application of digital environments in health.

Comparing digital health isolation with a mountain to climb, #sherpas20 is made up of ten groups: medicine, nursing, pharmacy, physiotherapy, health institutions, scientific societies, the pharmaceutical industry, patients, health communicators and a mixed group, made up of different professionals not represented in the previous groups.

Each of these groups is led by a Sardar Sherpa. They all met on 4 November 2014 at a conference held in Madrid where, thanks to the effort and work of the 50 representatives of Spanish eHealth, the conclusions of the report "Proposals to reduce the digital health divide" were reached.

Following the presentation of the report, it is the collective intelligence that has emerged from the #sherpas20 movement that must become the lever for change to move from isolation to the inclusion of the "unconnected" in health, and make more and more people and institutions unite and lead change in their organizations.

In November 2018, the III Conference was held in Madrid, where the first self-assessment test for non-healthcare professionals was presented, as well as the course "Keys to professional practice in health care settings 2.0", in collaboration with the Institute of Continued Education - IL3 of the University of Barcelona.

INS-224

GRUPO
MENARINI

Alfons XII, 587 • E-08918 Badalona (Barcelona)
Tel. +34 93 462 88 00 • Fax +34 93 462 88 20 • www.menarini.es